Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Lodi, Alessia ^a   Ronen, Sabrina M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALANINE; BETA ACTIN; CITRIC ACID; FUMARIC ACID; GLUTAMINE; GLUTATHIONE; INITIATION FACTOR 4E BINDING PROTEIN 1; LACTIC ACID; PHOSPHORYLCHOLINE; RAF PROTEIN; TANESPIMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL LEVEL; CELL METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; METABOLOMICS; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; BREAST TUMOR; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; METHODOLOGY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CITRIC ACID; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 80053934312     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026155     Document Type: Article

References (60)

1. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
2. Hsu PP, Sabatini DM, (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
3. Kaelin WG, Thompson CB, (2010) Q&A: Cancer: Clues from cell metabolism. Nature 465: 562-564.
4. Jones RG, Thompson CB, (2009) Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 23: 537-548.
5. Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, et al. (2008) Hyperpolarized 13C lactate, pyruvate, and alanine: Noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 68: 8607-8615.
6. Day SE, Kettunen MI, Gallagher FA, Hu D-E, Lerche M, et al. (2007) Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 13: 1382-1387.
7. Seth P, Grant A, Tang J, Vinogradov E, Wang X, et al. (2001) On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia 13: 60-71.
8. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, et al. (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39: 2012-2020.
9. Van den Abbeele AD, Ertuk M, (2008) FDG-PET to measure response to targeted therapy: The example of gastrointestinal stromal tumor and imatinib mesylate (Gleevec). PET Clinics 3: 77-87.
10. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, VanCriekinge M, et al. (2010) Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 70: 1296-1305.
11. Dafni H, Larson PEZ, Hu S, Yoshihara HAI, Ward CS, et al. (2010) Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and Myc activity downstream of platelet-derived growth factor receptor. Cancer Res 70: 7400-7410.
12. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM, (2006) Choline phospholipid metabolism in cancer: Consequences for molecular pharmaceutical interventions. Mol Pharm 3: 496-506.
13. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA, (2004) Proton magnetic resonance spectroscopic imaging of human breast cancer: A preliminary study. J Magn Reson Imaging 19: 68-75.
14. Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Coshic O, et al. (1998) Volume localized in vivo proton MR spectroscopy of breast carcinoma: Variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed 11: 414-422.
15. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, et al. (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.1-cm(3)) spatial resolution. Radiology 198: 795-805.
16. Mori N, Delsite R, Natarajan K, Kulawiec M, Bhujwalla ZM, et al. (2004) Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging 3: 319-323.
17. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, et al. (1999) Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Japanese Journal Cancer Research 90: 419-424.
18. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE, (1998) Human breast lesions: Characterization with proton MR spectroscopy. Radiology 209: 269-275.
19. Ross B, Michaelis T, (1994) Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 10: 191-247.
20. Yeung DKW, Cheung HS, Tse GMK, (2001) Human breast lesions: Characterization with contrast-enhanced in vivo proton MR spectroscopy- Initial results. Radiology 220: 40-46.
21. Al-Saffar NMS, Jackson LE, Raynaud FI, Clarke PA, de Molina AR, et al. (2010) The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 70: 5507-5517.
22. Beloueche-Babari M, Jackson LE, Al-Saffar NMS, Eccles SA, Raynaud FI, et al. (2006) Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther 5: 187-196.
23. Beloueche-Babari M, Peak JC, Jackson LE, Tiet MY, Leach MO, et al. (2009) Changes in choline metabolism as potential biomarkers of phospholipase C gamma 1 inhibition in human prostate cancer cells. Mol Cancer Ther 8: 1305-1311.
24. Brandes A, Ward C, Ronen SM, (2010) 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res 12: R84.
25. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, et al. (2003) Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 95: 1624-1633.
26. Jordan BF, Black K, Robey IF, Runquist M, Powis G, et al. (2005) Metabolite changes in HT-29 xenograft tumors following HIF-1α inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 18: 439.
27. Le HC, Lupu M, Kotedia K, Rosen N, Solit D, et al. (2009) Proton MRS detects Metabolic Changes in Hormone Sensitive and Resistant Human Prostate Cancer Model CWR22 and CWR22r. Magn Reson Med 62: 1112-1119.
28. Romanska HM, Tiziani S, Howe RC, Gunther UL, Guizar Z, et al. (2009) Nuclear magnetic resonance detects phosphoinositide 3-Kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts. Neoplasia 11: 1301-1308.
29. Ronen SM, Jackson LE, Beloueche M, Leach MO, (2001) Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 84: 691-696.
30. Sankaranarayanapillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, et al. (2008) Monitoring histone deacetylase inhibition in vivo: Noninvasive magnetic resonance spectroscopy method. Mol Imaging 7: 92-100.
31. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, et al. (2010) Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncology 12: 559-569.
32. Goetz MP, Toft DO, Ames MM, Erlichman C, (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Annals of Oncology 14: 1169-1176.
33. Clayton AT, Lindon JC, Cloarec O, Antti H, Charuel C, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077.
34. Holmes E, Loo RL, Stamler J, Bictash M, Yap IKS, et al. (2008) Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453: 396-400.
35. Tiziani S, Lopes V, Günther UL, (2009) Early stage diagnosis of oral cancer using 1H-NMR-based metabolomics. Neoplasia 11: 269-276.
36. Peet AC, McConville C, Wilson M, Levine BA, Reed M, et al. (2007) H-1 MRS identifies specific metabolite profiles associated with MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell lines. NMR Biomed 20: 692-700.
37. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, et al. (2009) Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One 4: e4251.
38. Lodi A, Tiziani S, Khanim FL, Drayson MT, Günther UL, et al. (2011) Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. ACS Chem Biol 6: 169-175.
39. Bathen TF, Jensen LR, Sitter B, Fjoesne HE, Halgunset J, et al. (2007) MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104: 181-189.
40. Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS, (2010) Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res 70: 6692-6696.
41. Chan ECY, Koh PK, Mal M, Cheah PY, Eu KW, et al. (2009) Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 8: 352-361.
42. Cheng LL, Burns MA, Taylor JL, He WL, Halpern EF, et al. (2005) Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 65: 3030-3034.
43. Sitter B, Bathen T, Hagen B, Arentz C, Skjeldestad FE, et al. (2004) Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. MAGMA Magn Reson Mater Phys Biol Med 16: 174-181.
44. Schnackenberg LK, Beger RD, Dragan YP, (2009) NMR-based metabonomics in toxicology research In: Vaidyanathan S, Harrigan GG, Goodacre RE, editors. Metabolome Analyses pp. 159-172 Strategies for Systems Biology. Springer.
45. Courtney KD, Corcoran RB, Engelman JA, (2010) The PI3K Pathway As Drug Target in Human Cancer. Journal of Clinical Oncology 28: 1075-1083.
46. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, et al. (2005) A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer. Clinical Prostate Cancer 4: 138-141.
47. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, et al. (2007) Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer. Clinical Cancer Research 13: 1775-1782.
48. Su JS, Woods SM, Ronen SM, (2011) Metabolic Consequences of PI3K/AKT signaling in MCF-7 Breast Cancer Cells. NMR Biomed doi:10.1002/nbm.1764.
49. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al. (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
50. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, et al. (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer cell 8: 143-153.
51. Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, et al. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
52. Regan PL, Jacobs J, Wang G, Torres J, Edo R, et al. (2011) Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol 38: 105-112.
53. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang X-Y, et al. (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787.
54. Cao MD, Sitter B, Bathen TF, Bofin A, Lønning PE, et al. (2011) Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed doi:10.1002/nbm.1762.
55. Perez-Ruiz A, Julia-Sape M, Mercadal G, Olier I, Majos C, et al. (2010) The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses. BMC Bioinformatics 11: 581.
56. Tate AR, Underwood J, Acosta DM, Julià-Sapé M, Majós C, et al. (2006) Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra. NMR Biomed 19: 411-434.
57. Hwang TL, Shaka AJ, (1995) Water suppression that works- Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J Magn Reson 112: 275-279.
58. Günther UL, Ludwig C, Ruterjans H, (2000) NMRLAB- Advanced NMR data processing in MATLAB. J Magn Reson 145: 201-208.
59. Dieterle F, Ross A, Schlotterbeck G, Senn H, (2006) Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in H-1 NMR metabonomics. Anal Chem 78: 4281-4290.
60. Parsons HM, Ludwig C, Günther UL, Viant MR, (2007) Improved classification accuracy in 1-and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation. BMC Bioinformatics 8: 234.